Google
Apple
English (UK)
English (India)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
BIOARCTIC AB (PUBL) |
Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 234 SEK | -2.17% | +0.95% | -13.97% | |
| Nov. 08 | Transcript : BioArctic AB, Q3 2023 Earnings Call, Nov 08, 2023 | CI |
| Nov. 08 | BioArctic AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
| Sales 2023 * | 547M 52.61M | Sales 2024 * | 725M 69.74M | Capitalization | 21.12B 2.03B |
|---|---|---|---|---|---|
| Net income 2023 * | 183M 17.6M | Net income 2024 * | 243M 23.37M | EV / Sales 2023 * | 37,2x |
| Net cash position 2023 * | 760M 73.13M | Net cash position 2024 * | 1.04B 100M | EV / Sales 2024 * | 27,7x |
| P/E ratio 2023 * | 115x | P/E ratio 2024 * | 87,1x | Employees | 83 |
| Yield 2023 * | - | Yield 2024 * | - | Free-Float | 44.13% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +0.17% | ||
| 1 week | +2.93% | ||
| Current month | +2.93% | ||
| 1 month | +10.33% | ||
| 3 months | -21.00% | ||
| 6 months | -25.58% | ||
| Current year | -12.06% |
1 week
230.00
244.20
1 month
208.00254.20
Current year
198.20392.00
1 year
198.20392.00
3 years
66.70392.00
5 years
47.00392.00
10 years
20.40392.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 76 | 2003 | |
| Chief Executive Officer | 62 | 2014 | |
| Founder | 74 | 2003 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Eugen Steiner
CHM | Chairman | 69 | 2016 |
| Director/Board Member | 55 | - | |
| Director/Board Member | 62 | 2021 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.96% | 4 M€ | -11.50% | - | |
| 1.25% | 4 M€ | +6.96% | ||
| 1.25% | 2 M€ | +3.19% | ||
| 0.89% | 14 M€ | -8.03% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-12-08 | 234 | -2.17% | 89 717 |
| 23-12-07 | 239.2 | +0.17% | 55,858 |
| 23-12-06 | 238.8 | 0.00% | 75,297 |
| 23-12-05 | 238.8 | +2.84% | 148,876 |
| 23-12-04 | 232.2 | +0.17% | 131,686 |
Delayed Quote Nasdaq Stockholm, December 07, 2023 at 11:29 am EST
More quotes
BioArctic AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of treatments, which aim at diseases that affect the central nervous system (CNS). Its therapeutic areas encompass neurodegenerative disorders, Alzheimer's disease, Parkinson's disease, complete spinal cord injury, as well as other CNS disorders. The Company owns a technology platform, which develops a range of therapeutic monoclonal antibodies. The Company's pipeline includes product candidates in various clinical phases, such as BAN2401, AE1501, BAN0805, imaging and biochemical biomarkers, BBB-technology and SC0806. The Company also operates through SpineMedical AB.
Calendar
2024-02-14
- Q4 2023 Earnings Release
Trading Rating :
Investor Rating :
ESG Refinitiv :
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
239.2SEK
Average target price
372.4SEK
Spread / Average Target
+55.69%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -12.06% | 2 030 M $ | |
| +69.89% | 41 191 M $ | |
| +4.93% | 39 236 M $ | |
| -55.49% | 30 484 M $ | |
| -27.50% | 27 837 M $ | |
| +38.06% | 22 079 M $ | |
| -25.41% | 22 245 M $ | |
| -1.81% | 16 633 M $ | |
| -12.95% | 11 376 M $ | |
| -17.93% | 10 762 M $ |
